| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Blueprint Medicines Corporation (NASDAQ: BPMC)
BPMC Technical Analysis
4
| As on 9th Jun 2023 BPMC STOCK Price closed @ 58.47 and we RECOMMEND Sell for LONG-TERM with Stoploss of 63.98 & Strong Sell for SHORT-TERM with Stoploss of 80.43 we also expect STOCK to react on Following IMPORTANT LEVELS. |
BPMCSTOCK Price
| Open | 56.69 | Change | Price | % |
| High | 59.15 | 1 Day | 1.86 | 3.29 |
| Low | 56.57 | 1 Week | 1.95 | 3.45 |
| Close | 58.47 | 1 Month | 9.85 | 20.26 |
| Volume | 411800 | 1 Year | -47.97 | -45.07 |
| 52 Week High 110.97 | 52 Week Low 37.97 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| BPMC Daily Charts |
BPMC Intraday Charts |
Whats New @ Bazaartrend |
BPMC Free Analysis |
|
|
BPMC Important Levels Intraday
| RESISTANCE | 63.44 |
| RESISTANCE | 61.85 |
| RESISTANCE | 60.86 |
| RESISTANCE | 59.88 |
| SUPPORT | 57.06 |
| SUPPORT | 56.08 |
| SUPPORT | 55.09 |
| SUPPORT | 53.50 |
BPMC Forecast May 2024
| 4th UP Forecast | 111.5 |
| 3rd UP Forecast | 94.49 |
| 2nd UP Forecast | 83.98 |
| 1st UP Forecast | 73.47 |
| 1st DOWN Forecast | 43.47 |
| 2nd DOWN Forecast | 32.96 |
| 3rd DOWN Forecast | 22.45 |
| 4th DOWN Forecast | 5.44 |
BPMC Weekly Forecast
| 4th UP Forecast | 70.67 |
| 3rd UP Forecast | 66.76 |
| 2nd UP Forecast | 64.34 |
| 1st UP Forecast | 61.92 |
| 1st DOWN Forecast | 55.02 |
| 2nd DOWN Forecast | 52.60 |
| 3rd DOWN Forecast | 50.18 |
| 4th DOWN Forecast | 46.27 |
BPMC Forecast2024
| 4th UP Forecast | 200.99 |
| 3rd UP Forecast | 155.28 |
| 2nd UP Forecast | 127.03 |
| 1st UP Forecast | 98.78 |
| 1st DOWN Forecast | 18.16 |
| 2nd DOWN Forecast | -10.09 |
| 3rd DOWN Forecast | -38.34 |
| 4th DOWN Forecast | -84.05 |
Blueprint Medicines Corporation ( NASDAQ USA Symbol : BPMC )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
BPMC Business Profile
Blueprint Medicines Corporation, a precision therapy company, develops medicines for people with cancer and hematologic disorders, and multiple programs for genomically defined cancers, systemic mastocytosis, and cancer immunotherapy in the United States and Europe. The company is developing avapritinib for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and fisogatinib, an orally available and potent inhibitor, which is in Phase 1b/2 trials for the treatment of advanced hepatocellular carcinoma. It is also developing pralsetinib for the treatment of RET-altered non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945, a selective and potent investigational inhibitors of double-mutant EGFR harboring, which are in preclinical stage for patient with EGFR-driven NSCLC. In addition, the company is developing BLU-782, an oral and investigational activin-like kinase 2 inhibitor, which is in Phase I clinical trials for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; CStone Pharmaceuticals; Genentech, Inc.; and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. Blueprint Medicines Corporation has a strategic research collaboration with The University of Texas MD Anderson Cancer Center for accelerating development of BLU-222, an investigational precision therapy that targets cyclin-dependent kinase 2. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts. Address: 45 Sidney Street, Cambridge, MA, United States, 02139-4133
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service